Vireo Growth (VREOF) Non-Current Assets (2020 - 2026)
Vireo Growth (VREOF) posted Non-Current Assets of $670.5 million for Q1 2026, up 30.93% sequentially from $512.1 million in Q4 2025, and up 1279.27% YoY from $48.6 million in Q1 2025.
Vireo Growth (VREOF) Non-Current Assets (2020 - 2026) Analysis & Trends
Vireo Growth has reported Non-Current Assets for 7 years, with the latest figure at $670.5 million in Q1 2026.
- Quarterly Non-Current Assets rose 1279.27% year-over-year to $670.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 884.23% YoY) and the FY2025 annual result came in at $512.1 million, up 956.06% from the prior year.
- Non-Current Assets improved to $670.5 million in Q1 2026 per VREOF's latest filing, from $512.1 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $670.5 million in Q1 2026 and troughed at $34.4 million in Q4 2023.
- A 5-year average of $162.8 million and a median of $49.9 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2026: Non-Current Assets tumbled 69.4% in 2023, then surged 1279.27% in 2026.
- Over 5 years, Non-Current Assets stood at $112.4 million in 2022, then sank by 69.39% to $34.4 million in 2023, then surged by 40.92% to $48.5 million in 2024, then surged by 956.06% to $512.1 million in 2025, then jumped by 30.93% to $670.5 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $670.5 million, $512.1 million, and $371.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 2.96 Bn |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn | 879.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 670.50 Mn |
| Dec 31, 2025 | 512.10 Mn |
| Sep 30, 2025 | 370.95 Mn |
| Jun 30, 2025 | 346.55 Mn |
| Mar 31, 2025 | 48.61 Mn |
| Dec 31, 2024 | 48.49 Mn |
| Sep 30, 2024 | 49.90 Mn |
| Jun 30, 2024 | 46.05 Mn |
| Mar 31, 2024 | 43.71 Mn |
| Dec 31, 2023 | 34.41 Mn |
| Sep 30, 2023 | 36.56 Mn |
| Jun 30, 2023 | 39.58 Mn |
| Mar 31, 2023 | 43.08 Mn |
| Dec 31, 2022 | 112.43 Mn |
| Sep 30, 2022 | 119.46 Mn |
| Jun 30, 2022 | 122.43 Mn |
| Mar 31, 2022 | 121.98 Mn |
| Dec 31, 2021 | 125.33 Mn |
| Sep 30, 2021 | 119.41 Mn |
| Jun 30, 2021 | 70.71 Mn |